Company: LGNZZ
Filing Date: 2025-12-18
Form Type: 8-K
Source: 0001193125-25-324830
Chunk: 0

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-12-18
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01      Regulation FD Disclosure.  

On December 18, 2025, Ligand Pharmaceuticals Incorporated (“ Ligand”) posted materials regarding its private placement investment in Athira Pharma, Inc. on its investor relations page and certain of its social media accounts.

Ligand announces material information to the public through filings with the Securities and Exchange Commission, the investor relations page on Ligand’s website, available at https://www. ligand. com/, press releases, public conference calls, webcasts, Ligand’s X (Twitter) account (@Ligand_LGND) and Ligand’s LinkedIn page, in order to achieve broad, non-exclusionarydistribution of information to the public and for complying with its disclosure obligations under Regulation FD.

The information disclosed by the foregoing channels could be deemed to be material information. As such, Ligand encourages investors, the media and others to follow the channels listed above and to review the information disclosed through such channels. Any updates to the list of disclosure channels through which Ligand announces information will be posted on the investor relations page on Ligand’s website.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                               LIGAND PHARMACEUTICALS INCORPORATED                                         
  Date: December 18, 2025      By:                                      /s/ Andrew Reardon                 
                               Name:                                    Andrew Reardon                     
                               Title:                                   Chief Legal Officer and Secretary